{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"No of participants who experience DLTs"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"No of participants who do not experience DLTs"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Will be descriptive and will be reported in tabular format with the appropriate summary statistics (count and percentage). In the dose-finding portion, the number of dose limiting toxicities (DLTs) identified among the DLT-evaluable subjects will be listed and summarized by dose level. The safety variables will be listed and summarized for (1) subjects in the dose-finding portion, (2) subjects in the dose expansion cohort (DEC), and (3) all subjects in the study.","groups":[{"description":"Each participant in the dose-finding cohort must have completed at least cycle 1 (or 21 days) of ibrutinib plus rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (EPOCH). Starting dose of ibrutinib is 560 mg PO.","id":"OG000","title":"Dose-finding Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participant who receive study treatment (Ibrutinib 560 mg)","reportingStatus":"POSTED","timeFrame":"Up to 21 days","title":"Maximum Tolerated Dose (MTD) of Ibrutinib in Combination With Chemotherapy","type":"PRIMARY","unitOfMeasure":"Participants"}